Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy

Pediatric Pulmonology

Volumn 48, Issue 9, 2013, Pages 912-920

  Buyse, Gunnar M ^a   Goemans, Nathalie ^a   Van Den Hauwe, Marleen ^a   Meier, Thomas ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Santhera Pharmaceuticals   (Switzerland)

Author keywords

Duchenne muscular dystrophy; glucocorticoids; idebenone; peak expiratory flow; respiratory function

Indexed keywords

CATENA; DEFLAZACORT; IDEBENONE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; EFFECT SIZE; FORCED VITAL CAPACITY; HUMAN; INTERVENTION STUDY; MALE; PEAK EXPIRATORY FLOW; PHASE 2 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; SCHOOL CHILD;

DUCHENNE MUSCULAR DYSTROPHY; GLUCOCORTICOIDS; IDEBENONE; PEAK EXPIRATORY FLOW; RESPIRATORY FUNCTION;

ADOLESCENT; ANTIOXIDANTS; CHILD; DOUBLE-BLIND METHOD; GLUCOCORTICOIDS; HUMANS; LUNG; MALE; MUSCLE STRENGTH; MUSCULAR DYSTROPHY, DUCHENNE; RESPIRATION; RESPIRATORY FUNCTION TESTS; RESPIRATORY MUSCLES; UBIQUINONE; VITAL CAPACITY;

EID: 84882416839     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22688     Document Type: Article

References (31)

1. Inkley SR, Oldenburg FC, Vignos PJ,. Pulmonary function in Duchenne muscular dystrophy related to stage of disease. Am J Med 1974; 56: 297-306.
2. Rideau Y, Jankowski LW, Grellet J,. Respiratory function in the muscular dystrophies. Muscle Nerve 1981; 4: 155-164.
3. McDonald CM, Abresch RT, Carter GT, Fowler WM Jr, Johnson ER, Kilmer DD, Sigford BJ,. Profiles of neuromuscular diseases: Duchenne Muscular Dystrophy. Am J Phys Med Rehabil 1995; 74: S70-S92.
4. Tangsrud S, Petersen IL, Lødrup Carlsen KC, Carlsen KH,. Lung function in children with Duchenne's muscular dystrophy. Resp Med 2001; 95: 898-903.
5. Kohler M, Clarenbach CF, Böni L, Brack T, Russi EW, Bloch KE,. Quality of life, physical disability, and respiratory impairment in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med 2005; 172: 1032-1036.
6. Finder JD, Birnkrant D, Carl J, Farber HJ, Gozal D, Iannaccone ST, Kovesi T, Kravitz RM, Panitch H, Schramm C, Schroth M, Sharma G, Sievers L, Silvestri JM, Sterni L,. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004; 170: 456-465.
7. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C,. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multi-disciplinary care. Lancet Neurol 2010b; 9: 177-189.
8. Birnkrant DJ, Bushby K, Amin RS, Bach JR, Benditt JA, Eagle M, Finder JD, Kalra MS, Kissel JT, Koumbourlis AC, Kravitz RM,. The respiratory management of patients with Duchenne muscular dystrophy: a DMD care consideration working group special article. Pediatr Pulmonol 2010; 45: 739-748.
9. Phillips MF, Quinlivan RC, Edwards RH, Calverley PM,. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular mystrophy. Am J Respir Crit Care Med 2001; 164: 2191-2194.
10. Vincken WG, Elleker MG, Cosio MG,. Flow-volume loop changes reflecting respiratory muscle weakness in chronic neuromuscular disorders. Am J Med 1987; 83: 673-680.
11. Hahn A, Bach JR, Delaubier A, Renardel-Irani A, Guillou C, Rideau Y,. Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne Muscular Dystrophy. Arch Phys Med Rehabil 1997; 78: 1-6.
12. Suárez AA, Pessolano FA, Monteiro SG, Ferreyra G, Capria ME, Mesa L, Dubrovsky A, De Vito EL,. Peak flow and peak cough flow in the evaluation of expiratory muscle weakness and bulbar impairment in patients with neuromuscular disease. Am J Phys Med Rehabil 2002; 81: 506-511.
13. Griggs R,. The use of pulmonary function testing as a quantitative measurement for therapeutic trials. Muscle Nerve 1990; 13: S30-S34.
14. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C,. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010a; 9: 77-93.
15. Manzur AY, Kuntzer T, Pike M, Swan A,. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008; CD003725: 1-65.
16. Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA,. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 2001; 138: 45-50.
17. Biggar WD, Harris VA, Eliasoph L, Alman B,. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006; 16: 249-255.
18. Daftary AS, Crisanti M, Kalra M, Wong B, Amin R,. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics 2007; 119: e320-e324.
19. Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier-Fruh I, Anklin C, Dallmann R, Gueven N,. NQO1-dependent redox-cycling of idebenone: effects on cellular redox potential and energy levels. PLoS ONE 2011; 6: e17963.
20. Becker C, Bray-French K, Drewe J,. Pharmacokinetic evaluation of idebenone. Expert Opin Drug Metab Toxicol 2010; 6: 1437-1444.
21. Buyse GM, Van der Mieren G, Erb M, D'hooge J, Herijgers P, Verbeken E, Jara A, Van Den Bergh A, Mertens L, Courdier-Fruh I, Barzaghi P, Meier T,. Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. Eur Heart J 2009; 30: 116-124.
22. Buyse GM, Goemans N, van den Hauwe M, Thijs D, de Groot IJ, Schara U, Ceulemans B, Meier T, Mertens L,. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. Neuromuscul Disord 2011; 21: 396-405.
23. Mertens L, Ganame J, Claus P, Goemans N, Thijs D, Eyskens B, Van Laere D, Bijnens B, D'hooge J, Sutherland GR, Buyse G,. Early regional myocardial dysfunction in young patients with DMD. J Am Soc Echocardiogr 2008; 21: 1049-1054.
24. Domenech-Clar R, Lopez-Andreu JA, Compte-Torrero L, De Diego-Damia A, Macian-Gisbert V, Perpina-Tordera M, Roques-Serradilla JM,. Maximal static respiratory pressures in children and adolescents. Pediatric Pulmonol 2003; 35: 126-132.
25. Godfrey S, Kamburoff PL, Nairn JR,. Spirometry, lung volumes and airway resistance in normal children aged 5 to 18 years. Brit J Dis Chest 1970; 64: 15-24.
26. Quanjer PH, Stocks J, Polgar G, Wise M, Karlberg J, Borsboom G,. Compilation of reference values for lung function measurements in children. Eur Respir J Suppl 1989; 4: 184S-261S.
27. Hibbert M, Lanigan A, Raven J, Phelan PD,. Relation of arm span to height and the prediction of lung function. Thorax 1988; 43: 657-659.
28. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K,. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002; 12: 926-929.
29. Bushby K, Muntoni F, Urtizberea A, Hughes R, Griggs R,. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Disord 2004; 14: 526-534.
30. Moxley RT, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, Baumbach L, McDonald C, Sussman M, Wade C,. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005; 64: 13-20.
31. Dohna-Schwake C, Ragette R, Teschler H, Voit T, Mellies U,. Predictors of severe chest infections in pediatric neuromuscular disorders. Neuromuscul Disord 2006; 16: 325-328.